Direct intralymphatic injection of peptide vaccines enhances immunogenicity

European Journal of Immunology

Volumn 35, Issue 2, 2005, Pages 568-574

  Johansen, P ^a   Haffner A C ^a   Koch, F ^a   Zepter, K ^a   Erdmann, I ^a   Maloy, K ^a   Simard, J J ^b   Storni, T ^a   Senti, G ^a   Bot, A ^b   Wuthrich B ^a   Kündig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MannKind Corp   (Spain)

Author keywords

CTL; Peptide; Route of administration; Vaccination; Virus

Indexed keywords

CD8 ANTIGEN; CYTOSINE DERIVATIVE; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN GP33; GUANINE DERIVATIVE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OLIGODEOXYNUCLEOTIDE; PEPTIDE DERIVATIVE; PROTEIN NP52; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; IMMUNOGENICITY; IMMUNOTHERAPY; INTERMETHOD COMPARISON; LYMPH NODE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; VACCINATION; VIRUS INFECTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNE SYSTEM; INJECTIONS, INTRALYMPHATIC; LYMPH; MICE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; VIRUS DISEASES;

EID: 20044366365     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425599     Document Type: Article

References (17)

1. Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C. and Boon, T., Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 1995. 145: 229-250.
2. Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I., Schumacher, T. N., Melief, C. J., Offringa, R. and Toes, R. E., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999. 5: 774-779.
3. Steinman, R. M., The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991. 9: 271-296.
4. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R., Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996. 2: 52-58.
5. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Garcia-Prats, M. D., DeLeo, A. B. and Lotze, M. T., Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997. 15: 94-103.
6. Dhodapkar, M. V., Steinman, R. M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S. M., Dunbar, P. R., Cerundolo, V., Nixon, D. F. and Bhardwaj, N., Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 1999. 104: 173-180.
7. Sallusto, F. and Lanzavecchia, A., Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994. 179: 1109-1118.
8. + dendritic cells. Proc. Natl. Acad. Sci. USA 1996. 93: 2588-2592.
9. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, F., Eibl, B., Niederwieser, D. and Schuler, G., Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 1996. 196: 137-151.
10. Reddy, A., Sapp, M., Feldman, M., Subklewe, M. and Bhardwaj, N., A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997. 90: 3640-3646.
11. Maloy, K. J., Erdmann, I., Basch, V., Sierro, S., Kramps, T. A., Zinkernagel, R. M., Oehen, S. and Kundig, T. M., Intralymphatic immunization enhances DNA vaccination. Proc. Natl. Acad. Sci. USA 2001. 98: 3299-3303.
12. Pircher, H., Moskophidis, D., Rohrer, U., Burki, K., Hengartner, H. and Zinkernagel, R. M., Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990. 346: 629-633.
13. Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J., Battegay, M., Lother, H., Gessner, A., Kuhlcke, K., Ohashi, P. S., Hengartner, H. et al., Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995. 268: 1343-1347.
14. + T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. J. Immunol. 1991. 146: 4301-4307.
15. Puddington, L., Bevan, M. J., Rose, J. K. and Lefrancois, L., N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells. J. Virol. 1986. 60: 708-717.
16. Krieg, A. M., CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002. 20: 709-760.
17. Zinkernagel, R. M., Leist, T., Hengartner, H. and Althage, A., Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 1985. 162: 2125-2141.